Arena Pharma (ARNA) Posts Narrower than Expected Q4 Loss
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Price: $99.98 --0%
Financial Fact:
Net loss per share allocable to common stockholders, diluted: -0.05
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Net loss per share allocable to common stockholders, diluted: -0.05
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Arena Pharmaceuticals (NASDAQ: ARNA) reported Q4 loss of $0.23, $0.02 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $4.01 million versus the consensus estimate of $4.81 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Range Impact, Inc. (RNGE) Reports Q2 Loss of $0.02
- Cellebrite DI Ltd. (CLBT) Tops Q2 EPS by 4c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
